International Journal of Life science and Pharma Reviews (IJLPR)  
International Journal of Life science and Pharma Research (IJLPR)
Pharmaceutical Sciences
Volume 2 Issue 2, April - June 2012    Pages:51-56
Simultaneous Estimation Of Lamivudine And Stavudine In Tablet Dosage Form By RP-HPLC

Jayaraman Anbu, C. Roosewelt, Ashwini Anjana, G. Srinivasa Rao And R. Sathish
[View PDF]
DOI: DOI not available
Lamivudine is a potent ‛‛reverse transcriptase inhibitor'' belonging to the class of nucleoside analog reverse transcriptase inhibitor (NARTI). Stavudine is an anti-HIV treatment drug in the class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). Both are excellent anti-retroviral drugs, widely used clinically in the treatment of infections which are related to immuno deficiency virus. The present combination of Lamivudine and Stavudine was marketed as one tablet dosage form formulation with a dose of Lamivudine 150mg/tab and Stavudine 40mg/tab. Although various methods have been developed for the estimation of Lamivudine and Stavudine individually and in combination with other drugs, no official method has been published with the combination of these drugs. The fixed dose combination of Lamivudine and Stavudine was subjected to simultaneous estimation by Reverse phase HPLC method.
Keywords: Lamivudine, Stavudine, Retroviral, HPLC, Nucleoside analog, Immuno virus.
© 2010-2015 IJLPR. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions